Emergent Biosolutions announced a $51 million contract from BARDA for the development of a new anthrax vaccine utilising their protective antigen rPA. This antigen stimulates a protective immune-response that neutralises the anthrax toxins – which has long been an element of concern.
Meanwhile Cleveland BioLabs snagged a $45 million contract from CBMS for their CBLB502 radiation countermeasure. $14.8 million of this is for advanced development of the countermeasure while the remained is for purchase, after FDA approval, of the necessary dosage for US Forces.
Smiths Detection announced that they had been awarded a five year contract from the Washington Area Metropolitan Transit Authority (WMATA) for a continuation of detection systems and an upgrade of their libraries and radiological detection. The system forms part of PROTECT, Program for Response Options and Technology Enhancements for Chemical/Biological Terrorism, and also includes their FirstView tool to provide enhanced C2 and incident management system – allowing networked CCTV and digital recording.